Farxiga

Name:
In the Primary Composite Endpoint in DAPA-CKD, Farxiga reached __%.  In EMPA- Kidney, Jardiance reached __ % in the Primary Composite Endpoint. Clinical trials are not equal and can not compare results.
Farxiga 28, Jardiance 39
Farxiga 39, Jardiance 39
Farxiga 39, Jardiance 28
Farxiga 28, Jardiance 39
In a post hoc endpoint of DAPA-CKD, Farxiga's All Cause Hospitalization was  __%.   Jardiance secondary endpoint of All Cause Hospitalization was __%
Farxiga 22, Jardiance 14
Farxiga 22, Jardiance 29
Farxiga 15, Jardiance 19
Farxiga 17, Jardiance 27
The Number Needed to Treat (NNT) for Farxiga in DAPA-CKD was 19.  What was the NNT for Jardiance in EMPA- Kidney?
23
27
25
29
In DAPA- CKD, there was a secondary endpoint of All Cause Mortality (ACM) , Farxiga reached statistical significance of 31%.
 
EMPA Kidney did not reach statistical significance in their secondary endpoint of ACM what percentage did Jardiance reach__%?
13
39
40
44
The number of patients in the study for DAPA-CKD was ____.  EMPA Kidney had 6609 in the study.
4000
4300
6405
4304
The Length of DAPA-CKD was___years and  EMPA Kidney study length was 2.0 years. 
2.0
2.4
3.0
3.5
In DAPA - CKD the UACR median was___.  EMPA Kidney the median UACR was 329.  
200
500
949
5000
{"name":"Farxiga", "url":"https://www.quiz-maker.com/QPREVIEW","txt":"Name:, In the Primary Composite Endpoint in DAPA-CKD, Farxiga reached __%.  In EMPA- Kidney, Jardiance reached __ % in the Primary Composite Endpoint. Clinical trials are not equal and can not compare results., In a post hoc endpoint of DAPA-CKD, Farxiga's All Cause Hospitalization was  __%.   Jardiance secondary endpoint of All Cause Hospitalization was __%","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}
Powered by: Quiz Maker